Neuroendokrin daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

15+ intézményből 15, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R43

  Development of a PET Imaging Platform to De-Risk AAV Gene Therapy Clinical Trials

  Neocell Technologies Inc· Fair Lawn, Egyesült Államok· 306 395 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, Egyesült Államok· 1 174 824 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Novel Non-Mutagenic Ribosome Biogenesis Inhibitors for the Treatment of Small Cell Lung Cancer

  Palade Therapeutics Inc.· Austin, Egyesült Államok· 404 087 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  High-Performance Next-Generation SPECT-CT (NxSPECT) for Theranostics

  Yale University· New Haven, Egyesült Államok· 532 637 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIBIB · U24

  Medical Imaging and Data Resource Center (MIDRC) – Expansion to Theranostics

  University of Chicago· Chicago, Egyesült Államok· 1 014 676 USD awarded in fiscal year 2026· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 321 301 EUR· until 2030. máj.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Írország· EU contribution 268 569 EUR· until 2029. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 4 574 378 EUR· until 2030. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norvégia· EU contribution 4 773 849 EUR· until 2030. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxemburg· EU contribution 14 837 694 EUR· until 2029. dec.· 13 countries

10 of 194 running projects, newest first. Listed amounts together: 116,1 M USD + 37,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Merck Sharp & Dohme LLC· Forrás

• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

  NCT04924075· Merck Sharp & Dohme LLC· Forrás

• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

  NCT04074135· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 201
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Assessment of Cell-Free MicroRNA by NGS Whole Transcriptome Analysis in Cutaneous Melanoma Patients' Blood.

  Methods Mol Biol, 2027. jan.

• Bulk Transcriptomic Inference in Vestibular Schwannoma is Sensitive to Estimated Cell Composition: Cross-Cohort Analysis and Single-Cell Lineage Annotation.

  J Mol Neurosci, 2026. nov.

• Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma.

  Med Oncol, 2026. okt.

• An m5C-associated NSUN5-YBX1-CENPF programme marks melanoma cell states and immune features.

  Front Immunol, 2026. okt.

• Molecular Mechanisms of the Anticancer Activity of Hinokitiol in C32 Melanoma Cells: Transcriptomic Analysis and Modulation by a Static Magnetic Field.

  Molecules, 2026. okt.

• Transcriptome Analysis of Linalool-Induced Hypopigmentation in B16 Melanoma Cells.

  Int J Mol Sci, 2026. okt.

• Can We Diagnose Early Melanoma by Genomics?

  Int J Dermatol, 2026. okt.

• Pan-Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM.

  Cancer Med, 2026. okt.

• Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey.

  Eur J Cancer, 2026. szept.

• Schwann Cell Expression Pattern in Human Melanomas: In Silico and Immunohistochemical Analyses.

  Int J Mol Sci, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.